Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
SAGA Metals Reports Assays from R-0018 to R-0020 with Intercepts Including 49.51% Fe?O?, 6.56% TiO?, 0.374% V?O? from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
Sirios Resources Inc. Closes Fully-Subscribed $25 Million Brokered LIFE Offering of Flow-Through Units and Units
RZOLV Reports Preliminary Bench-Scale Silver Recovery Results on Solar Panel Concentrate, Highlighting Opportunity for High-Value PV Recycling
